XLO XILIO THERAPEUTICS INC Investments/Divestments 8-K Filing 2024 - License Agreement with Gilead Xilio Therapeutics, Inc. has entered into a license agreement with Gilead Sciences, Inc. granting Gilead an exclusive global license to develop and commercialize Xilio's clinical-stage product candidate XTX301, with upfront payments of $43.5 million and potential additional contingent payments of up to $604.0 million.Get access to all SEC 8-K filings of the XILIO THERAPEUTICS INC